Gandotinib (LY2784544)

For research use only.

Catalog No.S2179

16 publications

Gandotinib (LY2784544) Chemical Structure

CAS No. 1229236-86-5

Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.

Selleck's Gandotinib (LY2784544) has been cited by 16 publications

3 Customer Reviews

  • HEL cells were treated for 3 hours with the indicated concentrations of LY2784544. LY2784544 inhibits Jak2-V617F mediated signal transduction at submicromolar concentrations in  intact cells.



    M.Sc. Karoline Gaebler and Dr. Claude Haan of Université du Luxembour. Gandotinib (LY2784544) purchased from Selleck.

  • Relative expression of BCLXL, c-MYC, CCND1, MMP2 and VEGF in (A) HL60 cell line. Cells were treated with 1 µM of ruxolitinib, fedratinib, gandotinib or tofacitinib for 6 h. RE=1 for DMSO control. Asterix (*) denotes statistical significance (p<0.05). Error bars denotes±standard deviation. Each relative expression value was obtained from at least two biological experiments run in two technical repeats.

    Eur J Pharmacol, 2015, 765:188-97. . Gandotinib (LY2784544) purchased from Selleck.

  • (F) SGC-7901 cells were treated with JAK2 specific inhibitor of LY2784544 (5 nM) for 1 h, and then p-JAK2 expressions were measured using western blot analysis. SGC-7901 cells were pretreated with LY2784544 (5 nM) for 1 h, followed by APG (50 mM) incubation for another 24 h. Following, (G) The cell viability and (H) apoptosis were calculated. ***P < 0.001 versus the Con group. ###P < 0.001 versus the IL-6 group; þþþP < 0.001 versus the IL-6/APG group. Data are represented as mean ± SEM (n = 8).

    Biochem Biophys Res Commun, 2018, 498(1):164-170. Gandotinib (LY2784544) purchased from Selleck.

Purity & Quality Control

Choose Selective JAK Inhibitors

Biological Activity

Description Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.
JAK2 (V617F) [1] JAK2 [1] JAK2 [1]
(Cell-free assay)
FLT3 [2] JAK1 [2]
0.245 nM(Ki) 0.288 nM(Ki) 3 nM 4 nM 19.8 nM
In vitro

LY2784544 also inhibits IL-3-activated wild type JAK2 with IC50 of 2.26 μM. Similarly in the proliferation assay, LY2784544 shows antiproliferation activity in JAK2 V617F-driven cells with IC50 of 68 nM, compared to 1.36 μM in wild type JAK2-driven cells and 0.94 μM in JAK3-driven cells. [1] Though biochemical assays do not reveal selectivity of LY2784544 for mutant JAK2V617F, LY2784544 shows higher selectivity for inhibition of JAK2-mediated signaling and induction of apoptosis in Ba/F3 cells expressing JAK2V617F than wild-type cells. [2]

In vivo LY2784544 significantly inhibits STAT5 phosphorylation in Ba/F3-JAK2 V617F-GFP xenografts with a Threshold Effective Dose 50 (TED50) of 12.7 mg/kg. LY2784544 also reduces Ba/F3-JAK2 V617F-GFP tumor burden in the JAK2 V617F-induced MPN model with a TED50 of 13.7 mg/kg after oral treatment. LY2784544 has no effect on CD71/Ter119 positive erythroid progenitors in spleens of SCID mice after oral treatment. [1]


Solubility (25°C)

In vitro DMSO 94 mg/mL (200.02 mM)
Ethanol 9 mg/mL (19.15 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 469.94


CAS No. 1229236-86-5
Storage powder
in solvent
Synonyms N/A
Smiles CC1=CC(=NN1)NC2=NN3C(=C(N=C3C(=C2)CN4CCOCC4)C)CC5=C(C=C(C=C5)Cl)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01520220 Completed Drug: LY2784544 Myeloproliferative Neoplasms of|Polycythemia Vera|Essential Thrombocythemia|Myelofibrosis Eli Lilly and Company June 11 2012 Phase 1
NCT01594723 Active not recruiting Drug: 120 mg LY2784544 Neoplasms Hematologic Eli Lilly and Company May 22 2012 Phase 2
NCT01577355 Completed Radiation: Drug Healthy Male Volunteers Eli Lilly and Company April 2012 Phase 1
NCT01134120 Completed Drug: LY2784544 Myeloproliferative Disorders|Thrombocythemia Essential|Polycythemia Vera|Primary Myelofibrosis Eli Lilly and Company April 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

JAK Signaling Pathway Map

JAK Inhibitors with Unique Features

Related JAK Products

Tags: buy Gandotinib (LY2784544) | Gandotinib (LY2784544) supplier | purchase Gandotinib (LY2784544) | Gandotinib (LY2784544) cost | Gandotinib (LY2784544) manufacturer | order Gandotinib (LY2784544) | Gandotinib (LY2784544) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID